Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.18 · Revenue $10.00M · 1 analysts
Est. EPS $-0.10 · Revenue $3.95M · 1 analysts
Est. EPS $-0.17 · Revenue $17.69M · 5 analysts
Est. EPS $-0.04 · Revenue $12.49M · 1 analysts
EPS $-0.17 · Revenue $7.34M
EPS $-0.17 · Revenue $7.34M
EPS $-3.33 · Revenue $5.00M
EPS $-0.81 · Revenue $2.50M
EPS $-4.89 · Revenue $0.00
EPS $-1.59 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $5.0M | — | 0.0% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-35.5M | +31.5% | 0.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | — | 0.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -714.0% | — | 0.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -710.6% | — | 0.0% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-33.7M | +35.1% | 0.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -674.5% | — | 0.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -316.9% | -396.7% | 0.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.65x | -54.3% | 0.0% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $34.4M | -51.7% | 0.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.33 vs -0.29 | -1028.8% | -0.17 vs -0.18 | +5.6% |
| Revenue Surprise | $5.0M vs $20.1M | -75.1% | $7.3M vs $10.0M | -26.6% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jan 1, 2029 | LU YANG | director, 10 percent owner, officer: CEO | Restricted Share Units | — | 100,000 | — |
| Aug 26, 2026 | Ye Xiaofeng | officer: CFO | American Depositary Shares | D | 5,667 | $14.25 |
| Aug 24, 2026 | Ye Xiaofeng | officer: CFO | American Depositary Shares | D | 6,000 | $13.98 |
| Jun 10, 2026 | Ji Ping | director | American Depository shares | A | 136,667 | — |
| May 28, 2026 | Ye Xiaofeng | officer: CFO | American Depositary Shares | — | 0 | — |
| Name | Title | Gender | Year Born | Status |
|---|---|---|---|---|
Zhiyong Yu | Vice President of Operations | — | — | Active |
Xiaofeng Ye | Chief Financial Officer | — | 1979 | Active |
Ngai Chiu Tse | President & Head of Research & Development | — | 1967 | Active |
Nanhai He | Head of Discovery | — | — | Active |
Donghui Yang | Chairman of the Greater China Region | Male | — | Active |
Yang Lu | Co- Founder, Chief Executive Officer & Chairman | Male | 1979 | Active |
Chen Yang | Head of HR & Administration & Government Affairs | Male | — | Active |
The consensus price target hints at an 81.8% upside potential for Adlai Nortye Ltd. Sponsored ADR (ANL).
Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed to Scientific Advisory Board SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.
Adlai Nortye (NASDAQ: ANL - Get Free Report) is projected to announce its Q2 2026 resultson Thursday, August 6th. Analysts expect Adlai Nortye to announce earnings of ($0.1333) per share and revenue of $3.95 million for the quarter. Individuals are encouraged to explore the company's upcoming Q2 2026 earning overview page for the latest details on
First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in process SINGAPORE and NORTH BRUNSWICK, N.J.
First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both QD and QW arms are now enrolling SINGAPORE and NORTH BRUNSWICK, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.
